IMBRUVICA® for Previously Treated Adult cGVHDIMBRUVICA® for Previously Treated Adult cGVHD

IMBRUVICA® (ibrutinib)
for Previously Treated
Adult cGVHD

IMBRUVICA® Is an Oral, Once-Daily cGVHD Medication That May Help When Other Systemic Therapies Have Failed 

IMBRUVICA® is the first FDA-approved therapy for adult chronic graft versus host disease (cGVHD) patients who have already been treated with other systemic therapies

Patients who aren’t getting results with steroid therapy have another option1

  • In a trial of previously treated patients, 2 out of 3 patients (28 of 42 patients enrolled in the study) had a response with IMBRUVICA®, which means they showed improvement1
  • Almost half of patients (20 of 42) in the trial had a response to IMBRUVICA® that lasted for at least 20 weeks

What should I know about IMBRUVICA® side effects?

IMBRUVICA® may cause serious side effects, including1:

  • Bleeding problems (hemorrhage)
  • Infections
  • Heart rhythm problems (ventricular arrhythmias, atrial fibrillation, and atrial flutter)
  • Heart failure and death
  • High blood pressure (hypertension)
  • Decrease in blood cell counts
  • Second primary cancers
  • Tumor lysis syndrome*

*TLS is a disorder caused by the fast breakdown of cancer cells, which can lead to kidney failure and other abnormalities.


The most common side effects in the adult cGVHD clinical trial were1:

  • Tiredness
  • Muscle spasms
  • Bruising
  • Nausea
  • Diarrhea
  • Bleeding (Hemorhage)
  • Low platelet counts
  • Low red blood cell count
  • Mouth sores (stomatitis)
  • Pneumonia

In the adult cGVHD clinical trial, nearly 1 in 4 patients stopped taking IMBRUVICA® because of side effects.1

This is not a complete list of side effects. Others may occur. Tell your doctor if you think you are experiencing side effects.

Reference: 1IMBRUVICA® (ibrutinib) Prescribing Information.

Pharmacyclics, an AbbVie Company, may collect your personal data through your online and offline interactions with us, including your contact, demographic, geolocation, and health-related data. We may also collect your online usage data automatically through cookies and similar technologies. We use this data for several purposes, such as to provide you with and improve our programs, services, and products, customize your experiences, and for research and analytics. We retain your personal data for as long as necessary to fulfill these purposes or to comply with our record retention obligations. We do not sell your personal data but may use and disclose your personal data with marketing and advertising partners to deliver you ads based on your interests inferred from your activity across other unaffiliated sites and services (“online targeted advertising”) and for website analytics. To opt out of the use or disclosure of your personal data for online targeted advertising or for website analytics, go to Your Privacy Choices on our website. For more information on the personal data categories we collect, the purposes for their collection, our disclosures to third parties, your data subject rights, and our data retention criteria, visit our Privacy Notice.

Through my submission of the program enrollment form, I consent to the collection, use, and disclosure of my personal health data, as described in the Privacy Notice above and in AbbVie’s Privacy Notice in the How We May Disclose Personal Data section. My consent is required to process sensitive personal data under certain privacy laws, and I have the right to withdraw my consent by visiting Your Privacy Choices on AbbVie’s website.

IMBRUVICA® (ibrutinib) is covered by U.S. Patents, which are listed in FDA's Orange Book (available at